Given the high global prevalence of nonalcoholic fatty liver disease (NAFLD), the need for relevant noninvasive biomarkers and algorithms to accurately stage disease severity is a critical unmet medical need. Identifying those with advanced fibrosis (≥ F3) is the most crucial, as these individuals have the greatest risk of adverse, long-term, liver-related outcomes. We aimed to investigate the role of PRO-C3 (a marker of type III collagen formation) as a biomarker for advanced fibrosis in NAFLD. We 
T he increase in global prevalence of metabolic syndrome has been accompanied by a rise in organ damage including end-stage disease related to nonalcoholic fatty liver disease (NAFLD). Estimates place the worldwide prevalence of NAFLD at 25%. (1) A subset of these patients develop non alcoholic steatohepatitis (NASH) that can progress to cirrhosis and are at a high risk of adverse liver-related outcomes. (1) From a management and therapeutic perspective, an unmet clinical need is the requirement to distinguish those with early disease from those at highest risk of clinical complications. Although metabolic hepatic inflammation is the milieu that drives disease progression, various studies (including meta analyses) that have examined for prognostic histological features suggest that fibrosis stage is the parameter that best associates with overall-related and liver-related mortality, as well as liver transplantation and liver-related events. (2) (3) (4) (5) The gold standard for the evaluation of liver fibrosis stage is percutaneous needle biopsy, which is compromised by inherent sampling and interobserver biases and periprocedural risk. (6, 7) The invasiveness and costs of performing biopsies also makes it unsuitable for mass screening, for staging, and risk stratification. The latter is important as most patients with advanced fibrosis and even cirrhosis are asymptomatic and often indistinguishable from those at earlier disease stages. (8, 9) In this context, there is a need for surrogate markers of disease stage that can identify and risk-stratify patients with NAFLD. This area of research can broadly be divided into liquid (typically blood based) or physical approaches (measurement of liver stiffness). Physical approaches, although promising, are less useful for population-level screening and are limited by cost and other technique-specific considerations. Several serum-based biomarker tests have previously been developed and applied to NAFLD patients. (10) (11) (12) (13) (14) These scores typically combine clinical features and routine laboratory tests and are used primarily to rule out advanced fibrosis (15) ; however, they lack sufficient diagnostic accuracy and sensitivity.
Liver fibrosis is characterized by the accumulation of excess extracellular matrix; hence, biomarkers reflecting structural changes occurring in the hepatic extracellular matrix during chronic injury may be of value in the assessment of fibrosis progression or regression. We recently demonstrated that PRO-C3, a disintegrin and metalloproteinase with thrombospondin motifs-generated neo-epitope marker of type III collagen formation, is a marker of fibrosis in patients with chronic hepatitis C. The role of PRO-C3 in patients with NAFLD, however, is largely unknown. Because the performance of biomarkers and noninvasive liver fibrosis scores varies widely according to disease etiology, whether PRO-C3 has a role as a biomarker in NAFLD is unclear. In this study, we sought to (1) explore the association of PRO-C3 with liver fibrosis in two large independent biopsy-proven cohorts with NAFLD and (2) determine whether PRO-C3 can be combined with simple and routinely available clinical variables into a score for the prediction of advanced fibrosis in patients with NAFLD. We compared the performance of our derived model with other known biomarker algorithms.
Materials and Methods

StUDy popUlatIoN
A total of 431 well-phenotyped patients with biopsy-confirmed NAFLD comprised the study cohort. The derivation cohort included 150 patients All patients were referred for the investigation of abnormal liver tests or steatosis detected by ultrasound. The diagnosis of NAFLD was established by liver biopsy in all cases. Patients with disease of other etiologies including viral hepatitis and autoimmune liver disease were excluded by standard clinical, laboratory, and histopathological assessments. Patients with evidence of hepatic decompensation, secondary causes of steatosis including excess alcohol (men, >30 g/day; women, >20 g/day), total parenteral nutrition, or the use of drugs known to precipitate steatosis were excluded.
Demographic and clinical data were obtained, including age, gender, ethnicity, height, weight, and waist circumference at the time of biopsy. Body mass index (BMI) was calculated as BMI = kg/m 2 . Arterial hypertension was defined as blood pressure greater than or equal to 130/greater than or equal to 85 mmHg or treatment with antihypertensive drugs. Diabetes was defined as a fasting blood glucose greater than or equal to 7.0 mmol/L, previous diagnosis of diabetes, or use of antidiabetic drugs. Hyperlipidemia was defined as fasting total cholesterol over 5.5 mmol/L, triglycerides over 1.7 mmol/L, or treatment with lipid-lowering drugs. Ethical approval and written informed consent from patients were obtained from all participating centers.
HIStology
All biopsies were routinely stained with hematoxylin and eosin and Masson's Trichrome. The stained sections were read and scored by an expert liver pathologist at each participating center using the scoring system proposed by Kleiner et al. (16) (17) Thirty-one biopsies were scored independently by pathologists from the various centers, and interobserver agreement was calculated using the κ statistic and was equal to 0.55 for fibrosis, comparable to previously published results. (18) (19) (20) (21) 
BIoMaRKeR QUaNtIFICatIoN
At the time of biopsy, a fasting blood sample was obtained and routine biochemical tests were performed using standard methods and assays. Biochemical tests included albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, gamma-glutamyltransferase (GGT), insulin, high-density lipoprotein (HDL), lowdensity lipoprotein (LDL), platelets, and triglycerides. Additional blood samples were drawn and frozen at −80°C for future research. Type III collagen formation was assessed in serum using the PRO-C3 competitive enzyme-linked immunosorbent assay from Nordic Bioscience (Herlev, Denmark) as previously described. (22) The AST to platelet ratio index (APRI), FIB-4, and NAFLD fibrosis scores (NFS) were calculated using clinical and routine laboratory variables and previously defined algorithms and cut-off values for NAFLD/NASH patients. (10, 12, 14, 23) 
StatIStICal aNalySIS
The main aim of this study was to develop an algorithm consisting of clinical and laboratory variables that could accurately distinguish patients with advanced fibrosis (F ≥ 3) from those without. To this end, patients in the derivation cohort were stratified into those with advanced fibrosis (F ≥ 3) and those without (F0-F2). Stage 2 and 3 for lobular and portal inflammation was pooled as only 1 patient in both groups was graded stage 3. Continuous variables in the two groups were compared using the Student t test and categorical variables were compared using Fisher's exact test. Comparisons among mean marker levels were performed using the Kruskal-Wallis test followed by Dunn's multiple comparison test. Variables that were significantly different between patients with advanced fibrosis and those without advanced fibrosis were identified as potential algorithm components.
For the formulation of predictive models, variables showing a P less than 0.05 at univariate analysis (Student t test for parametric variables, and X 2 or Fisher exact test for frequencies) were included. The interaction between these variables was first tested. Variables explaining a statistically significant proportion of the variance (P < 0.05) were maintained in the model using the likelihood ratio (LR) test. The model variables were selected using the leave-one-out method to facilitate the calculation of overfit biasreduced estimates. (24) To avoid overfitting, 10-fold cross validations were used in the tree-building process.
The model was as follows:
The discriminative ability of the model for the identification of severe fibrosis (F ≥ 3) was assessed by means of receiver operating characteristic (ROC) curve analysis and expressed as area under the receiver operating characteristic curve (AUROC). A cut-off value to distinguish patients with advanced fibrosis from those without was determined using the bootstrap Youden Index. The diagnostic accuracy of the algorithm and the derived cutoff was determined by calculating sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). To overcome both spectrum effect and ordinal scale issues, we undertook two approaches. First, we used the Obuchowski measure, as proposed by Lambert et al., (25, 26) which is a measure of the probability that 2 randomly chosen patients from different fibrosis stages are correctly classified according to the weighted scheme, with a penalty for incorrect classification. In the second method, we standardized the AUROC for the distribution of fibrosis stages as proposed by Poynard et al., (27) as recently described. (28) ROC curves were also calculated for the established diagnostic scores, APRI, FIB-4, and NFS. Sensitivity, specificity, PPV, NPV, positive and negative likelihood ratios, and 95% confidence intervals (CIs) were calculated. Estimates of AUROCs and comparisons between AUROCs were performed using the method suggested by Hanley and McNeil. (29) Validation was subsequently performed on the validation cohort as well as for the combined overall cohort.
All data are shown as medians and variation expressed via Tukey plots. P values less than 5% were considered significant. Model building and statistical analysis was performed using MedCalc version 16.8.4 (MedCalc Software, Ostend, Belgium) and SAS version 9.1 (SAS Institute, Cary, NC). Graphs were designed using GraphPad Prism version 7 (GraphPad Software, La Jolla, CA).
Results
patIeNt CHaRaCteRIStICS
The characteristics of the 150 NAFLD patients used to develop the model (derivation cohort) and the 281 used to test the model (validation cohort) are given in Table 1 . Serum levels of albumin, AST, cholesterol, and HDL were all significantly lower in the validation cohort when compared with the derivation cohort. In addition, both BMI and insulin level were found to be significantly elevated. No other significant differences were observed between the two cohorts. The prevalence of severe fibrosis was not significantly different between the cohorts.
pRo-C3 IS HIgHly aSSoCIateD WItH SeVeRIty oF FIBRoSIS aND HIStologICal paRaMeteRS
Within the derivation cohort, PRO-C3 was found to be significantly elevated in patients with advanced fibrosis (F ≥ 3) compared with the mild/moderate group (P < 0.0001). PRO-C3 was highly associated with disease severity (Fig. 1 ) and moderately correlated with the severity of fibrosis (Rho = 0.501, P < 0.0001). PRO-C3 was able to discriminate between the following stages of fibrosis ( Fig. 1 ): F0 versus F2 (27% increase, P < 0.0332), F0 versus F3 (54% increase, P < 0.0001), F1 versus F3 (36% increase, P < 0.0002), and F0 versus F4 (57% increase, P < 0.0021). In addition, PRO-C3 discriminated among the various stages of hepatocyte ballooning (stage 0 versus stage 1, P = 0.001; stage 0 versus 2, P = 0.0003), lobular inflammation (stage 0 versus stage 1, P = 0.0004; stage 0 versus stages 2 and 3, P = 0.0008), and steatosis (stage 1 versus stage 3, P = 0.003).
We undertook logistic regression to discern the effect of various clinical variables on the association of PRO-C3 with the presence of advanced fibrosis (F ≥ 3) within the derivation cohort. In this analysis, Abbreviations: FBS, fasting blood sugar; ns, not significant.
FIg. 1.
PRO-C3 is highly related to histological parameters of NAFLD histological staging according to Kleiner et al. (16) : A) fibrosis stage (Rho = 0.50, P < 0.0001), B) ballooning stage (Rho = 0.38, P < 0.0001), C) steatosis stage (Rho = 0.29, P = 0.0003), D) lobular inflammation (Rho = 0.36, P < 0.0001), E) portal inflammation (Rho = 0.25, P = 0.003), and F) NAFLD activity score (NAS) (Rho = 0.46, P < 0.0001). *P < 0.0332; **P < 0.0021; ***P < 0.0002; ****P < 0.0001. PRO-C3, when adjusted for age, ALT, AST, BMI, ballooning, lobular inflammation, presence of diabetes, GGT and platelet count, was independently associated with advanced fibrosis (odds ratio [OR] = 1.054, 95% CI 1.01-1.07) ( Table 2 ). The AUROC for the identification of patients with advanced fibrosis (F ≥ 3) of PRO-C3 alone was 0.81 (95% CI 0.74-0.87) (data not shown).
ClINICal paRaMeteRS aSSoCIateD WItH tHe leVel oF pRo-C3
Given that univariate and multivariate analyses revealed that the level of PRO-C3 was a strong predictor of advanced fibrosis, we examined for clinical parameters associated with the level of PRO-C3. It was subsequently found that ALT (Rho 0.29, P = 0.0004), AST (Rho 0.42, P < 0.0001), fasting blood glucose (Rho 0.23, P = 0.007), insulin level (Rho 0.43, P < 0.0001), platelet count (Rho − 0.24, P = 0.004), and presence of diabetes (Rho 0.16, P = 0.05) all correlated with the level of PRO-C3 to varying degrees.
DeVelopMeNt oF a pRo-C3-BaSeD pReDICtIVe FIBRoSIS SCoRe
Based on the finding that PRO-C3 is strongly associated with fibrosis, we sought to build a model for the prediction of significant fibrosis based on PRO-C3 and routinely assessed clinical and laboratory variables. Patients within the derivation cohort were divided into two groups according to NASH Clinical Research Network fibrosis stage, F0-F2 (no fibrosis to moderate fibrosis) and F3-F4 (advanced fibrosis) (Table 3) . PRO-C3 was elevated in patients with advanced fibrosis compared with the mild to moderate group (P < 0.0001). Furthermore, those with advanced fibrosis had significantly increased levels of AST, GGT, and a higher AST/ALT ratio ( Table 3) . As would be expected, patients with advanced fibrosis had a worse metabolic profile with lower LDL, higher circulating insulin levels, and a higher waistto-hip ratio ( Table 3 ). The presence of diabetes was more likely in patients with advanced fibrosis; 67% of patients with F3-F4 had diabetes compared with just 29% of the F0-F2 group (P = 0.002) ( Table 3 ). In addition, patients with advanced fibrosis were found to be older (P = 0.02) and with a lower platelet count compared with those without (P = 0.002) ( Table 3 ).
Variables that were significantly different between the two groups (P < 0.05) were considered eligible for the model-building process. Those that described a statistically significant proportion of the variance were included in the model using the LR test. Ultimately, the variables that were included within the model were age, presence of diabetes, platelet count, and PRO-C3 (named "ADAPT").
The diagnostic capability of the ADAPT score was assessed via AUROC and was higher than that of PRO-C3 alone, yielding an AUROC of 0.86 (95% CI 0.79-0.91) (Fig. 2) .
ValIDatIoN oF tHe DIagNoStIC CapaBIlItIeS oF tHe aDapt SCoRe
To ascertain the validity of our model, the ability of ADAPT to identify patients with advanced fibrosis was corroborated in a separate cohort consisting of patients from four centers across Asia-Pacific and Europe (n = 281). Several significant differences were identified between the derivation and the validation cohort; these differences reflect the heterogeneity of NAFLD patients with advanced fibrosis. Despite cohort differences, the diagnostic accuracy of ADAPT was maintained with an AUROC in the validation cohort of 0.87 (95% CI 0.83-0.91) (Fig. 3) . The diagnostic performance of a score, when assessed by AUROC, may vary according to disease prevalence, known as spectrum bias. (30) The Obuchowski measure accounts for the spectrum bias and provides a means by which the diagnostic accuracy of a score can be assessed. The Obuchowski measure of ADAPT within the derivation cohort was calculated to be 0.86, and within the validation cohort it was 0.89. Additionally, we standardized the AUROC for the distribution of fibrosis stages according to Poynard et al. (27) The standardized AUROC of ADAPT was found to be 0.89 and 0.89 within the derivation and validation cohorts, respectively (Table 4 ). For further confirmation of the generalizability of the model, the validation cohort was stratified into various groups according to age (< 50, 50-60, and > 60), BMI, sex, NASH versus nonalcoholic fatty liver (NAFL), and center. In this analysis, ADAPT remained a robust algorithm in that the AUROC was maintained across all subpopulations, with NPV consistently exceeding 90% (Supporting Fig. S1 ).
peRFoRMaNCe oF aDapt agaINSt StaNDaRD algoRItHMS
Within the derivation cohort the AUROC of ADAPT (AUROC = 0.855) was superior to clinically available serum-based noninvasive scores: APRI (AUROC = 0.73, P = 0.02), FIB-4 (AUROC = 0.78, P = 0.06), and NFS (AUROC = 0.78, P = 0.06) (Table 4) . Likewise, in the validation cohort, the AUROC of ADAPT (AUROC = 0.87) was greater than APRI (AUROC = 0.78, P = 0.0005), FIB-4 (AUROC = 0.85, P = 0.32), and NFS (AUROC = 0.79, P = 0.02) ( Table 4) . Adjusting the AUROC according to Poynard et al (27) caused minor increases in the AUROC in all scores (Table 4) . Further investigation into the ability of ADAPT to identify patients with clinically significant fibrosis (F2-F4) highlighted the superiority of the ADAPT score when compared with other clinically available serum-based noninvasive scores (Supporting Table S3 ).
DeRIVatIoN oF CUt-oFF ValUeS
The derivation cohort was subjected to ROC curve analysis to derive a cut-off value for the rule-in and rule-out of advanced fibrosis. A value of greater than 6.3287 for the rule in/out of advanced fibrosis was identified by the Youden Index, PPV = 48.4%, NPV = 96.6% (Supporting Table S2 ). By applying this cutoff, 73% (n = 158) of F0-F2 patients were correctly classified and 27% (n = 58) were incorrectly classified. Among the F3-F4 patients, 92% (n = 60) were correctly classified whereas 8% (n = 5) were incorrectly classified (Table 5 ). We applied previously derived cut-off values for APRI (rule in advanced fibrosis > 1.5, rule out advanced fibrosis < 0.5), FIB-4 (rule in advanced fibrosis > 2.67, rule out advanced fibrosis < 1.3), and NFS (rule in advanced fibrosis > 0.676, rule out advanced fibrosis < − 1.455). (10, 14, 23) A large proportion of patients fell within an indeterminate zone (Table 5) . FIB-4 and APRI showed reasonable performance at identifying patients without advanced liver fibrosis, as 68% (n = 147) and 67% (n = 145) were correctly classified, respectively. However, these scores performed poorly at identifying patients with advanced liver fibrosis, with NFS and FIB-4 correctly identifying 51% (n = 33) and 46% (n = 30) of patients, respectively.
Discussion
In this study, we measured PRO-C3 in NAFLD patients from centers across the world and with a wide variation in ages and clinical manifestations, similar to that observed in daily clinical practice. The principal findings were as follows: (1) PRO-C3 progressively increases with fibrosis severity in NAFLD but the association remains highly significant even after adjustment for multiple biochemical and clinical parameters; and (2) PRO-C3 when combined with routine clinical parameters (ADAPT) generated a highly accurate tool for the detection of advanced fibrosis in NAFLD. ADAPT is therefore a unique score that has utility for risk stratification and for the clinical management of patients with NAFLD.
Noninvasive biomarkers that reflect the process of hepatic fibrosis are urgently needed; collagen formation biomarkers are therefore attractive targets. Here we demonstrate that PRO-C3, which measures type III collagen synthesis, is a precise marker for advanced liver fibrosis in concordance with what we have recently shown in chronic hepatitis C. (22, 31, 32) Notably, a recent small nonbiopsy study (n = 297) from a phase III study of balaglitazone in patients with late-stage type 2 diabetes (BALLET study) suggested that PRO-C3 could have utility as a determinant of treatment response to a potential antifibrotic therapy. (33) Karsdal et al. subsequently confirmed this within a study investigating the antifibrotic efficacy of farglitazar (33) ; Harrison et al. further explored PRO-C3 as a determinant of treatment response within a phase IIb study. (34) Although that finding needs to be validated in biopsy-proven cohorts, their data in combination with our findings suggest that PRO-C3 could serve as a biomarker not only for prediction of fibrosis progression, but also for treatment response. Interestingly, the optimal cut-off value in our study was 15.6 ng/mL for advanced fibrosis, which is significantly different from that in patients with hepatitis C (20 ng/mL). (35) Consistently, the cut-off level for PRO-C3 was also lower in the BALLET report (13.1 ng/mL). (33) Further studies will be required to confirm the optimal cutoff in NAFLD. It is noteworthy that the levels of PRO-C3 did not increase from F3 to F4. The explanation for this finding is not clear and further mechanistic studies are required.
Previous reports have suggested that the propeptide of type III collagen (22, 36) can be used as a biomarker for NASH. However, we have shown that PRO-C3 is distinct from PIIINP in that it is a true marker of type III collagen formation, and by extension, fibrogenesis. (22) We subsequently developed a PRO-C3-based fibrosis score for NAFLD patients and compared it with various composite serum-based score systems that have been proposed and tested in NAFLD patients, namely APRI, FIB-4, and the NFS. The AUROCs for the various scores examined in this study all performed similar to previous reports for the identification of advanced fibrosis. (23, 27, 37, 38) In contrast, ADAPT was superior, as in the multinational validation cohort. Critically, ADAPT was robust at identifying patients with advanced fibrosis across different subpopulations (diabetics versus nondiabetics, NAFL versus NASH, various age ranges and BMI categories), some of which have been shown to confound noninvasive algorithms. (39, 40) The AUROC of ADAPT was maintained at greater than 0.80 for all subpopulations, whereas the PPV and NPV remained consistent. From a management perspective, after the application of a derived cut-off value, ADAPT correctly classified 74% of patients without advanced fibrosis and 92% with advanced fibrosis. The cut-off values for APRI, FIB-4, and NFS were applied to our patients; similar to previous reports, we found that a large proportion of patients fell within an indeterminate zone. (37) FIB-4 and APRI showed reasonable performance at identifying patients without advanced fibrosis, but performed poorly at identifying patients with advanced fibrosis. Furthermore, the superiority of ADAPT is exemplified by its robust performance across various subpopulations (Supporting Table  S1 ) and by the substantially higher NPV. In contrast, the performance of FIB-4 has been demonstrated to be variable and is affected by confounders such as age. Additionally, unlike FIB-4, ADAPT is unburdened by the presence of an intermediate zone, which hinders its accuracy. (37, (40) (41) (42) (43) An advantage of PRO-C3, when used alone or in combination as in ADAPT, is that it may stratify cirrhosis, as the score is on a spectrum. This contrasts with FIB-4 or the NFS, which are based on a dichotomous threshold. Hence, PRO-C3-based scores may have potential in patient monitoring over time, although this needs validation.
In contrast to the other noninvasive scores, ADAPT is distinct in that it combines PRO-C3 with important clinical and metabolic parameters associated with disease severity. Both increased age and the presence of diabetes are well-established risk factors for progressive liver disease and are easily discerned. (44) Similarly, platelet count is routinely measured and is strongly correlated with liver fibrosis and has been incorporated into multiple other noninvasive scoring systems. (10, 12, 14) A study by Mofrad et al. has shown that the full spectrum of liver fibrosis stages can be found in patients presenting with liver enzymes in the normal range. (8) In addition, liver enzymes are sensitive to age, leading to false positive results. Thus, previous analyses have shown that FIB-4 (and likely also APRI and NFS) cannot be universally applied without modification to all patient groups. (40) The lack of inclusion of liver enzymes in ADAPT is therefore a conspicuous advantage.
Noninvasive tests have been proposed as screening tools for detecting advanced liver fibrosis in the general population, in which the prevalence of this outcome is low. (45) Score systems such as ADAPT, which exhibit a high specificity and NPV, could provide a useful tool for clinicians as they reduce any uncertainty surrounding the diagnosis and the number of follow-up assessments required. (45) We propose that the ADAPT score could be used as such a screening tool within the general population to identify patients at risk of or with advanced fibrosis, such that interventions could be applied and progression to cirrhosis perhaps mitigated. However, further validation in nonreferral cohorts and demonstration of the costeffectiveness of using PRO-C3-based score systems is first required.
Our study has some limitations that must be acknowledged. We included well-characterized biopsied patients from centers with an interest in studying NAFLD; therefore, referral bias cannot be ruled out. Biopsies were read by an independent pathologist at each participating center using a well-defined and standardized score system. In our work, the kappa value for assessing the severity of fibrosis has previously been shown to be good. (20) As previously described by Ratziu et al., liver biopsy as a diagnostic tool has several limitations including sampling bias. (6) However, all noninvasive diagnostic tools for fibrosis assessment are benchmarked against the biopsy. Thus, the use of an imperfect reference standard may result in underperformance of the accuracy of noninvasive scores. Additionally, because of the nature of this cross-sectional study, we could not follow the clinical progress of patients; it would be of interest to investigate the relationship of score classification with patient outcome.
In conclusion, a biomarker score based on PRO-C3 and clinical variables (ADAPT) accurately predicts the presence or absence of advanced fibrosis in a NAFLD population. Thus, ADAPT could be useful for risk stratification and management. Further independent studies will be required to determine whether patient stratification using ADAPT followed by measurement of liver stiffness can replace the need for liver biopsy as a diagnostic standard in NAFLD.
